Mirum Pharmaceuticals/$MIRM
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Mirum Pharmaceuticals
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
- Ticker
- $MIRM
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 433
- Headquarters
- Foster City, United States
- Website
- www.mirumpharma.com
MIRM Metrics
BasicAdvanced
$5.4B
-
-$15.34
0.51
-
Price and volume
Market cap
$5.4B
Beta
0.51
52-week high
$130.00
52-week low
$63.23
Average daily volume
836K
Financial strength
Current ratio
2.856
Quick ratio
2.62
Long term debt to equity
-72.975
Total debt to equity
-73.206
Interest coverage (TTM)
-7.16%
Profitability
EBITDA (TTM)
-70.283
Gross margin (TTM)
81.72%
Net profit margin (TTM)
-139.18%
Operating margin (TTM)
-15.57%
Effective tax rate (TTM)
-0.31%
Revenue per employee (TTM)
$1,430,000
Management effectiveness
Return on assets (TTM)
-6.79%
Return on equity (TTM)
-702.97%
Valuation
Price to revenue (TTM)
7.574
Price to book
-518.44
Price to tangible book (TTM)
-20.96
Price to free cash flow (TTM)
-17.75
Free cash flow yield (TTM)
-5.63%
Free cash flow per share (TTM)
-4.701
Growth
Revenue change (TTM)
44.02%
Earnings per share change (TTM)
1,173.67%
3-year revenue growth (CAGR)
74.77%
3-year earnings per share growth (CAGR)
47.27%
What the Analysts think about MIRM
Analyst ratings (Buy, Hold, Sell) for Mirum Pharmaceuticals stock.
Analyst projections of the future price of Mirum Pharmaceuticals stock.
Bulls say / Bears say
LIVMARLI sales rose 46% year on year in Q2 and total product sales reached $176.2 million. Mirum raised its 2026 sales guidance to $680 million–$700 million, showing strong momentum from its existing medicines. (Mirum Pharmaceuticals)
Brelovitug met the Phase 3 AZURE-1 primary endpoint in both dose groups, with response rates of 56% and 45% against 0% for delayed treatment. A positive AZURE-4 result could support a US filing targeted for the first half of 2027. (Mirum Pharmaceuticals, Fierce Biotech)
FDA approval of Atebrioz gives Mirum a new medicine for FOP and broadens its commercial portfolio. In the 24-week study supporting approval, lesion volume fell in treated patients while it increased on placebo. (Mirum Pharmaceuticals)
The FDA recommended an additional Phase 3 study for volixibat in PSC, and Mirum now targets a potential NDA submission in the first half of 2027. The regulatory setback delays this pipeline opportunity and leaves its route to approval uncertain. (Mirum Pharmaceuticals)
Mirum reported a $67.2 million net loss in Q2 despite $176.2 million in product sales, with operating expenses of $219 million. The gap shows that rapid sales growth has not yet translated into profitability, while continued development and launch spending weighs on results. (Mirum Pharmaceuticals, Simply Wall St)
Atebrioz enters a very small FOP market and faces an approved rival from Regeneron. The study supporting Mirum's approval was small, and the difference in the number of patients developing new bone growth did not reach statistical significance, which leaves uptake and differentiation uncertain. (Fierce Pharma)
Data summarised monthly by Lightyear AI. Last updated on 9 Oct 2026.
MIRM Financial Performance
Revenues and expenses
MIRM Earnings Performance
Company profitability
Upcoming events
No upcoming events
MIRM News
AllArticlesVideos
Mirum Pharmaceuticals' LIVMARLI Study Hits Key Endpoints in Rare Liver Diseases
MarketBeat1 week ago
Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases
Business Wire1 week ago
Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases
Business Wire2 weeks ago
Funds containing MIRM
Fund name | Fund size | $MIRM weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.36% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.36% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.14% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.14% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | $3.2B | 0.04% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.